Business Description
Cassiopea SpA
ISIN : IT0005108359
Description
Cassiopea SpA is a clinical-stage specialty pharmaceutical company. It is focused on developing and commercializing differentiated medical dermatology products. The company's focus is on the topical treatment of acne; Androgenic Alopecia, (or AGA); and genital warts. Its portfolio comprises four unencumbered clinical candidates namely: Winlevi, for the treatment of acne; Breezula, for the topical treatment of AGA; CB-06-02, for the treatment of genital warts; and CB-06-01, for the treatment of acne.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.29 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.63 | |||||
| Debt-to-EBITDA | -0.49 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 1.2 | |||||
| 3-Year EPS without NRI Growth Rate | 7.1 | |||||
| 3-Year FCF Growth Rate | 13.3 | |||||
| 3-Year Book Growth Rate | -20.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -21.9 | |||||
| 12-1 Month Momentum % | -28.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.69 | |||||
| Quick Ratio | 0.48 | |||||
| Cash Ratio | 0.21 | |||||
| Days Inventory | 1057.09 | |||||
| Days Payable | 2005.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -84.86 | |||||
| ROA % | -65.25 | |||||
| ROIC % | -84.78 | |||||
| ROC (Joel Greenblatt) % | -1480.01 | |||||
| ROCE % | -83.29 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 35.63 | |||||
| Price-to-Tangible-Book | 50.46 | |||||
| EV-to-EBIT | -30.87 | |||||
| EV-to-EBITDA | -31.03 | |||||
| EV-to-FCF | -28.26 | |||||
| Earnings Yield (Greenblatt) % | -3.24 | |||||
| FCF Yield % | -3.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cassiopea SpA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | |||
| EPS (TTM) (CHF) | -1.333 | ||
| Beta | 0 | ||
| Volatility % | 20 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (CHF) | 0 | ||
| 20-Day SMA (CHF) | 0 | ||
| 12-1 Month Momentum % | -28.07 | ||
| 52-Week Range (CHF) | 29 - 53 | ||
| Shares Outstanding (Mil) | 10.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cassiopea SpA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cassiopea SpA Stock Events
| Event | Date | Price(CHF) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cassiopea SpA Frequently Asked Questions
What is Cassiopea SpA(CHIX:SKINZ)'s stock price today?
The current price of CHIX:SKINZ is CHF32.80. The 52 week high of CHIX:SKINZ is CHF53.00 and 52 week low is CHF29.00.
When is next earnings date of Cassiopea SpA(CHIX:SKINZ)?
The next earnings date of Cassiopea SpA(CHIX:SKINZ) is .
Does Cassiopea SpA(CHIX:SKINZ) pay dividends? If so, how much?
Cassiopea SpA(CHIX:SKINZ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers